CLOVIS ONCOLOGY INC

NASDAQ: CLVS
$6.97
-$0.52 (-6.9%)
Closing price September 18, 2020
Wednesday's top analyst upgrades, downgrades and initiations included Agilent Technologies, American Power, Apache, Boeing, Ciena, Cisco, FireEye, Palo Alto Networks, Sony, Southwest Airlines and...
Tuesday's top analyst upgrades, downgrades and initiations included Apple, Blackstone, CBS, Global Payments, Netflix, Ralph Lauren, Walt Disney and Wynn Resorts.
The top analyst upgrades, downgrades and initiations on Tuesday included Advanced Micro Devices, Apple, Barrick Gold, Domino's Pizza, Intel, McDonald's, Occidental Petroleum and Salesforce.com.
The top analyst upgrades, downgrades and initiations seen on Friday included Shopify, Qualcomm, Pinterest, Sprouts Farmer's Market, BlackLine, Fortinet and Carbon Black.
Clovis Oncology may have thought that it could sneak an announcement by late on Friday, but its shares were definitely paying the price Monday morning.
Clovis Oncology shares jumped on Tuesday after the European Patent Office upheld the company’s claims.
IBM, General Electric, McDermott International, and Clovis Oncology all posted new 52-week lows Wednesday.
The top analyst upgrades, downgrades and initiations seen on Wednesday included Aetna, Baker Hughes, Chesapeake Energy, Cognizant Technology Solutions, Cummins, Eli Lilly, General Electric, Qualcomm...
Keycorp, eBay, Schlumberger, and Clovis Oncology all posted new 52-week lows Monday.
Clovis Oncology shares dropped on Friday after the company announced initial data from its Phase 2 clinical trial of Rubraca at the ESMO 2018 Congress.
Clovis Oncology shares jumped on Tuesday after the U.S. Food and Drug Administration (FDA) gave a critical update.
Clovis shares might not be showing it now, but the company is facing some heat from the SEC over charges of misleading investors about the company’s developmental lung cancer drug.
With 2018 coming to a close in just a few months, Merrill Lynch is taking a close look at the biotech industry and what key catalysts to expect before 2019.
Clovis Oncology shares saw a bump early on Thursday after the company announced that the European Medicines Agency has validated its application for a Type 2 variation to the marketing authorization...
These are three totally different plays that all have huge upside potential for investors able to commit some of their more speculative capital to these trades.